First Trust Advisors’s Heron Therapeutics HRTX Stock Holding History

First Trust Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-25,661	Closed	-$416K	–	2512
2021 Q1	$416K	Buy	25,661 +7,708	+43%	+$137K	﹤0.01%	2262
2020 Q4	$380K	Sell	17,953 -28,496	-61%	-$495K	﹤0.01%	2179
2020 Q3	$688K	Buy	46,449 +22,398	+93%	+$349K	﹤0.01%	1915
2020 Q2	$354K	Sell	24,051 -65,204	-73%	-$1.07M	﹤0.01%	2105
2020 Q1	$1.05M	Buy	89,255 +65,735	+279%	+$1.24M	﹤0.01%	1598
2019 Q4	$553K	Buy	+23,520	New	+$520K	﹤0.01%	2086
2019 Q2	–	Sell	-75,331	Closed	-$1.84M	–	2470
2019 Q1	$1.84M	Buy	75,331 +4,335	+6%	+$113K	﹤0.01%	1594
2018 Q4	$1.84M	Sell	70,996 -70,149	-50%	-$1.93M	﹤0.01%	1530
2018 Q3	$4.47M	Sell	141,145 -3,615	-2%	-$135K	0.01%	1213
2018 Q2	$5.62M	Buy	+144,760	New	+$4.61M	0.01%	1033

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

First Trust Advisors's HRTX Position: Q2 2021 in Review

First Trust Advisors sold out of Heron Therapeutics (HRTX) in Q2 2021, closing a stake of 25,661 shares — an estimated $416K sold.

First Trust Advisors first reported a position in HRTX in Q2 2018 and held it in 10 quarters. The position peaked at $5.62M in Q2 2018. 189 funds tracked by Wall St. Rank hold HRTX as of Q2 2021.

First Trust Advisors reported no remaining Heron Therapeutics position as of Q2 2021 after selling out during the quarter.
First Trust Advisors sold 25,661 Heron Therapeutics shares in Q2 2021, an estimated $416K.
First Trust Advisors first reported a position in Heron Therapeutics in Q2 2018 and held it in 10 quarters.
First Trust Advisors's Heron Therapeutics position peaked at $5.62M in Q2 2018.
189 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2021.

Based on First Trust Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.